SAMN38144277
External Id
dbGaP
INSDC center name
2023-11-07T12:13:49.953Z
INSDC first public
2024-05-30T05:49:11.793Z
INSDC last update
SRS19518613
INSDC secondary accession
live
INSDC status
Generic
NCBI submission model
Generic.1.0
NCBI submission package
SRS19518613
SRA accession
NCI_Pembrolizumab_MIBC
biospecimen repository
patient_121_CD3_C1_RNA-Seq
biospecimen repository sample id
CD3-positive PBMC
body site
phs003452
gap_accession
1
gap_consent_code
DS-CA
gap_consent_short_name
5699550
gap_sample_id
4645000
gap_subject_id
No
is tumor
Homo sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
organism
female
sex
Case Set
study design
Urinary Bladder Neoplasms
study disease
Phase 2 Study of Pembrolizumab in Combination with Gemcitabine and Cisplatin as Neoadjuvant Therapy
study name
Yes
subject is affected
patient_121_CD3_C1_RNA-Seq
submitted sample id
patient_121
submitted subject id
NCI_Pembrolizumab_MIBC
submitter handle
Non-tumor sample from CD3-positive PBMC of a human female participant in the dbGaP study "Phase 2 Study of Pembrolizumab in Combination with Gemcitabine and Cisplatin as Neoadjuvant Therapy"
title